LAS VEGAS, Feb. 28, 2023 /PRNewswire/ — Zoomlion Heavy Industry Science & Technology Co., Ltd. (“Zoomlion”; 1157.HK) is set to exhibit 22 products across seven categories, including equipment customized for the North American market, and its innovative green manufacturing technologies to CONEXPO-CON/AGG 2023 from March 14 to 18 in Las Vegas Convention Center. Zoomlion will… Continue reading Zoomlion to Exhibit Intelligent Human-Machine Interaction Technology and Green Manufacturing Achievements at CONEXPO-CON/AGG 2023
Category: Newswire
Felix Kilbertus is Pininfarina’s new Chief Creative Officer
TORINO, Italy, Feb. 28, 2023 /PRNewswire/ — Pininfarina appoints world-renowned automotive designer Felix Kilbertus as the new Chief Creative Officer. Felix will be the creative and strategic guide at Group level on all aspects of Design (Mobility, Product & Experience Design and Architecture). Reporting directly to CEO Silvio Angori, he will supervise all the Pininfarina… Continue reading Felix Kilbertus is Pininfarina’s new Chief Creative Officer
Bullet Train Market to Reach $77.57 Billion, Globally, by 2031 at 6.27% CAGR: Allied Market Research
An increase in the allocation of the budget for the development of railways, a rise in demand for secure, safer, & efficient transport, and an increase in the use of public transport services as a solution to minimize traffic congestion drive the growth of the bullet train market. PORTLAND, Ore., Feb. 28, 2023 /PRNewswire/ —… Continue reading Bullet Train Market to Reach $77.57 Billion, Globally, by 2031 at 6.27% CAGR: Allied Market Research
Felix Kilbertus is Pininfarina’s new Chief Creative Officer
TORINO, Italy, Feb. 28, 2023 /PRNewswire/ — Pininfarina appoints world-renowned automotive designer Felix Kilbertus as the new Chief Creative Officer. Felix will be the creative and strategic guide at Group level on all aspects of Design (Mobility, Product & Experience Design and Architecture). Reporting directly to CEO Silvio Angori, he will supervise all the Pininfarina… Continue reading Felix Kilbertus is Pininfarina’s new Chief Creative Officer
Felix Kilbertus is Pininfarina’s new Chief Creative Officer
TORINO, Italy, Feb. 28, 2023 /PRNewswire/ — Pininfarina appoints world-renowned automotive designer Felix Kilbertus as the new Chief Creative Officer. Felix will be the creative and strategic guide at Group level on all aspects of Design (Mobility, Product & Experience Design and Architecture). Reporting directly to CEO Silvio Angori, he will supervise all the Pininfarina… Continue reading Felix Kilbertus is Pininfarina’s new Chief Creative Officer
Bullet Train Market to Reach $77.57 Billion, Globally, by 2031 at 6.27% CAGR: Allied Market Research
An increase in the allocation of the budget for the development of railways, a rise in demand for secure, safer, & efficient transport, and an increase in the use of public transport services as a solution to minimize traffic congestion drive the growth of the bullet train market. PORTLAND, Ore., Feb. 28, 2023 /PRNewswire/ —… Continue reading Bullet Train Market to Reach $77.57 Billion, Globally, by 2031 at 6.27% CAGR: Allied Market Research
Nordic Nanovector ASA Results for the Second Half and Full Year 2022
OSLO, Norway, Feb. 28, 2023 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) announces its results for the second half and full year 2022. A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes will be held in-person today in Oslo and webcast live beginning at 8:30am CET – details below.… Continue reading Nordic Nanovector ASA Results for the Second Half and Full Year 2022
Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration
STOCKHOLM, Feb. 28, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review… Continue reading Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration
Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration
STOCKHOLM, Feb. 28, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review… Continue reading Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration
Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration
STOCKHOLM, Feb. 27, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review… Continue reading Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration